Once weekly, smaller needle, no nodules and look at where it is indicated.
"The FDA said that the safety and efficacy of Trulicity, a glucagon-like peptide-1 (GLP-1) receptor agonist, had been studied in 3,342 type 2 diabetics. The drug can be given as monotherapy or in combination with other diabetes drugs including metformin, sulfonylurea, thiazolidinediones, and prandial insulin"
Can be used with PRANDIAL INSULIN because it is known that QW GLP1's have more effect on fasting than PPG. Which is why BYD has no indication with basal and simply does not work for PPG. Lilly's indications for Trulicity will reinforce to physicians the limitations of BYD and how they have be misled to believe it is interchangeable with Byetta and Victoza.
"The FDA said that the safety and efficacy of Trulicity, a glucagon-like peptide-1 (GLP-1) receptor agonist, had been studied in 3,342 type 2 diabetics. The drug can be given as monotherapy or in combination with other diabetes drugs including metformin, sulfonylurea, thiazolidinediones, and prandial insulin"
Can be used with PRANDIAL INSULIN because it is known that QW GLP1's have more effect on fasting than PPG. Which is why BYD has no indication with basal and simply does not work for PPG. Lilly's indications for Trulicity will reinforce to physicians the limitations of BYD and how they have be misled to believe it is interchangeable with Byetta and Victoza.
Trulicity-Lilly's QW is approved
Aucun commentaire:
Enregistrer un commentaire